LIFT-AD Phase 2/3 Failure The larger LIFT-AD trial fails both primary and key secondary endpoints, raising questions about the clinical viability of fosgonimeton
These may or may not be realized by the Ontario health care system or individual institutions and are often based on evidence from the medical literature, standard listing references, and educated hypotheses from expert panels
Serious side effects are less common, but require emergency or urgent medical attention, and may include: Pancreatitis (inflammation of the pancreas) Gallbladder problems Hypoglycemia, or low blood sugar, when Mounjaro is used in combination with insulin or certain diabetes medicines Allergic reactions Kidney problems (this typically occurs with dehydration) Severe stomach problems Diabetic retinopathy problems Steps for getting Mounjaro If you are thinking about using Mounjaro, call your healthcare provider
Prenatal diagnosis of cleft lip and palate: detection rates, accuracy of ultrasonography, associated anomalies, and strategies for counseling
Trends in Endocrinology and Metabolism (2017) 7
